CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas

LOS ANGELES, April 19, 2017 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR) today announced the U.S. Food and Drug Administration (FDA) has reached an agreement with CytRx on preparations for a New Drug Application (NDA) submission for...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials